[Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy].

Autor:	Knyazev OV; Loginov Moscow Clinical Scientific Center.; Ryzhykh National Medical Research Center of Coloproctology.; Research Institute of Health Organization and Medical Management., Khomeriki SG; Loginov Moscow Clinical Scientific Center., Kagramanova AV; Loginov Moscow Clinical Scientific Center., Lishchinskaya AA; Loginov Moscow Clinical Scientific Center., Smirnova OA; Loginov Moscow Clinical Scientific Center., Noskova KK; Loginov Moscow Clinical Scientific Center., Parfenov AI; Loginov Moscow Clinical Scientific Center.
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2021 Dec 15; Vol. 93 (12), pp. 1435-1442. Date of Electronic Publication: 2021 Dec 15.
DOI:	10.26442/00403660.2021.12.201212
Abstrakt:	Aim: To conduct comparative analysis of histological remission in patients with moderate and severe ulcerative colitis (UC), receiving biological therapy vedolizumab, mesenchymal stem cell (MSC) treatment and combined stem cells and vedolizumab therapy. Materials and Methods: We studied biopsies of 75 patients with total or left-sided moderate and severe ulcerative colitis, divided into groups depending on treatment. The first group of UC patients (n=29) received stem cell therapy 2 mln per kg; the second group of UC patients (n=27) received vedolizumab and the third group (n=19) MSC and vedolizumab. The efficacy of treatment was assessed by C reactive protein (CRP), Mayo score (MS), fecal calprotectin (FC) and Geboes score (GS). Results: We determined medium correlation between basic FC and MS before treatment (r=0.6605, p0.05). After 12 weeks of treatment in the first group of UC patients (n=29) CRP was 7.82.1 mg/l, FC 409.344.85 g/g, medium GS 1.20.1 points. After 12 weeks of treatment in the second group of UC patients (n=27) CRP was 8.41.4 mg/l, FC 435.547.3 g/g, medium GS 1.350.15 points. After 12 weeks of treatment in the third group of UC patients (n=19) CRP was 6.41.1 mg/l, FC 290.617.5 g/g, medium GS 0.90.1 points. We proved strong direct relationship between FC and GS after 12 weeks of treatment in UC patients, receiving MSC (r=0.8392, p0.05). The statistically significant majority of patients, achieved histological remission, have less than 5-year duration of disease. Conclusion: Our study showed that clinical and endoscopic remission in UC patients does not always correlate with histological remission. Combined anti-cytokine and stem cells therapy contributes to achieve deep remission and decrease mucosa inflammation rather than single MSC or vedolizumab treatment. Deep remission could be achieved by earlier start of biological therapy. FC could be a predictor and marker of mucosa healing and histological remission.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu